Excellent
Fully Aligned
Patient Risk:
Low
Summary
The evaluated claim about increased myopathy risk with specific concomitant agents is directly supported by the provided FDA label text and contains no contradictions.
Category Scores
Accurate Statements
The risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole).
Supported by label warnings/precautions and drug interaction information: (1) 5.1 Skeletal Muscle: “The risk of myopathy… is increased with concurrent administration of cyclosporine, fibric acid derivatives, … clarithromycin, … niacin, or azole antifungals.” and (2) 5.1 Skeletal Muscle: “The concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of myopathy/rhabdomyolysis.” plus (3) provided interaction text: “The risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole) …”.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The statement accurately reflects labeled increased myopathy risk with the specified concomitant drug classes/agents; no missing or conflicting safety details were identified for the narrow claim as written.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement